JMIR Diabetes
Emerging technologies, medical devices, apps, sensors, and informatics to help people with diabetes
Editor-in-Chief:
Ricardo Correa, MD, EdD (Co-Editor-in-Chief), Cleveland Clinic, United States Sheyu Li, MD (Co-Editor-in-Chief), West China Hospital, Sichuan University, China
Impact Factor 2.6 More information about Impact Factor CiteScore 4.7 More information about CiteScore
Recent Articles

Effective management of type 2 diabetes mellitus (T2DM) requires monitoring clinical parameters like blood glucose and medication, alongside lifestyle factors such as diet and physical activity. Decision support tools, including dashboards and shared decision-making tools, help with medication adjustments, glucose monitoring, and lifestyle. However, systems rarely integrate home-monitored lifestyle data with personalized guidance and rarely facilitate collaborative goal setting for behavior change. As a result, health care professionals (HCPs) are limited in their ability to support patients’ medical and lifestyle management. Blended care, combining in-person consultations with digital monitoring of patient data, can help bridge this gap by providing structured information and data-driven insights to support diabetes management.

Type 1 diabetes is a constraining disease due to the burden of its management, and diabetes outcome largely depends on the effectiveness of diabetes self-care. Digital health technology (DHT), which includes continuous glucose monitoring, insulin delivery devices, and related mobile health apps, can support diabetes self-care and thereby improve diabetes outcomes. In literature, experiences with the use of DHT vary widely among people with diabetes and are a less studied area among adults with type 1 diabetes.

No preview text available.

Type 2 diabetes affects 483 million adults worldwide, with rising prevalence and an estimated 6 million premature deaths annually. Low physical activity is a key risk factor, while increased activity can reduce disease onset and improve metabolic health. Consumer activity trackers, when paired with behavior change strategies, have shown potential to increase physical activity among adults with type 2 diabetes.

For adults living with type 1 diabetes (T1D), diabetes-specific mental health support is limited. Peer support and digital health platforms are promising strategies for delivering this support to this population, particularly those from geographically marginalized communities. Mobile apps, in particular, can enhance self-management and deliver support. This paper describes the iterative co-design and development process of a novel mobile app for use in a pilot trial, T1D REACHOUT (REACHOUT), that aims to reduce the diabetes distress, a core facet of diabetes-specific mental health, of adults with T1D. An initial think tank and 6 focus groups were conducted with adults with T1D to better understand their support needs and identify platform requirements. Following this, we partnered with adults living with T1D, the “end users,” to iteratively co-design the REACHOUT app, enhancing usability and ensuring relevance. Adapting the open-source Rocket.Chat platform to user-defined requirements, we deployed the app in a single cohort pilot study. A network analysis of messages exchanged during the pilot study was performed to explore trends and patterns and demonstrate implementation feasibility. Pilot study outcomes informed further refinement before implementation in a randomized controlled trial. The implementation of the REACHOUT app features 6 key components identified in 6 initial focus groups: a 24/7 chatroom (a customized group messaging function with threads), topic-specific discussion boards, a peer supporter library, peer supporter profiles for a user-driven matching process, small group virtual sessions, and direct (one-to-one) messaging. Forty-six participants were encouraged to use any or all of the features as frequently as desired over a 6-month period during the pilot study. During this time, 179 private small groups were created, and 10,410 messages were sent, including 1389 chat room messages and 7116 direct messages; among these were 3446 messages exchanged between participants and their self-selected peer supporters. Key factors for successful implementation included (1) the co-design process involving comprehensive user engagement and (2) the opportunities realized through hybrid development. These findings offer generalizable lessons for mobile health research teams developing similar app-based interventions.

Digital health interventions, including artificial intelligence (AI)-driven solutions, offer promise for type 2 diabetes mellitus (T2DM) and prediabetes management through enhanced self-management, adherence, and personalization. However, engagement challenges and barriers, particularly among young adults and diverse populations, persist. Existing reviews emphasize clinical outcomes while neglecting engagement factors crucial to intervention success. This review highlights engagement barriers and facilitators, offering insights into improving digital health solutions for diabetes management.


The global prevalence of type 2 diabetes mellitus (T2DM) poses significant challenges due to its association with increased cardiovascular risk and complications like cardiovascular autonomic neuropathy. Measures derived from heart rate variability (HRV) and cardiorespiratory interactions quantified through frequency response function (FRF) and impulse response (IR) metrics reflect different aspects of autonomic regulation and may provide complementary physiological information relevant to diabetes-related autonomic alterations.


Older adults with diabetes frequently access their electronic health record (EHR) notes but often report difficulty understanding medical jargon and nonspecific self-care instructions. To address this communication gap, we developed SEE-Diabetes (Support-Engage-Empower-Diabetes), a patient-centered, EHR-integrated diabetes self-management support tool designed to embed tailored educational statements within the Assessment and Plan section of clinical notes.

Sulphonylureas are commonly prescribed for managing type 2 diabetes, yet treatment responses vary significantly among individuals. Although advances in machine learning (ML) may enhance predictive capabilities compared to traditional statistical methods, their practical utility in real-world clinical environments remains uncertain.
Preprints Open for Peer Review
Open Peer Review Period:
-






